Case Study: Major global biopharmaceutical company achieves streamlined early clinical development and simplified oversight with IQVIA (CRO solution provider)

A PORTFOLIO APPROACH TO EARLY CLINICAL DEVELOPMENT

The clinical research organization (CRO) needed to streamline end-to-end early clinical support for a major global biopharmaceutical sponsor across a diverse portfolio and multiple therapeutic areas, requiring deep operational and scientific expertise. They engaged IQVIA and its Early Clinical Development & Precision Medicine Integrated Platform to centralize capabilities and provide integrated early‑clinical services.

IQVIA provided early engagement and strategic planning—placing subject‑matter experts in sponsor planning sessions, hosting in‑house symposia, assigning a single global delivery lead, and applying continuous process improvements (including FMEA)—to deliver centralized oversight and cross‑functional capabilities (cardiac safety, imaging, clin pharm units, patient recruitment, PK modeling, precision medicine, etc.). The engagement delivered simplified oversight and contracting, earlier insight into compound viability, and a sustainable, trust‑based partnership that promoted innovation, mutual advocacy, and alignment across the portfolio.